HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.

AbstractPURPOSE:
O6-benzylguanine (BG) provides a means to effectively inactivate the DNA repair protein O6-alkylguanine-DNA alkyltransferase (AGT) and increase the chemotherapeutic effectiveness of chloroethylating and methylating agents in preclinical and clinical studies. Two different doses of BG have been reported as the optimal biochemical modulatory dose for patients (i.e., 100 and 120 mg/m2). The objective of our study was to compare these doses by measuring AGT in surgically removed specimens after treatment with BG.
EXPERIMENTAL DESIGN:
BG was administered to patients as an i.v. infusion 16 +/- 4 h before surgical resection of their systemic tumor. AGT activity was measured in the tumor using a methylated DNA substrate. The target end point was defined as > or =11 of 13 patients with undetectable tumor AGT levels (<10 fmol/mg protein).
RESULTS:
Of the 28 patients enrolled, 25 of whom were analyzed for AGT activity, the most common primary sites of cancer included the colon (n = 11), bladder (n = 3), rectum (n = 4), and stomach (n = 3). Positive (DaOY cells) and negative (Chinese hamster ovary cells) control cell lines were included in each assay. Seven of the 12 patients treated with 100 mg/m2 BG had AGT activity of >10 fmol/mg protein (15-147 fmol/mg protein). Only 2 of the 13 patients treated with 120 mg/m2 BG had AGT activity of >10 fmol/mg protein (11 and 12 fmol/mg protein).
CONCLUSIONS:
From our surgically removed tissue data, a dose of 120 mg/m2 BG is recommended to deplete systemic tumors of AGT activity.
AuthorsM Eileen Dolan, Mitchell Posner, Theodore Karrison, Jonathan Radosta, Gary Steinberg, Donna Bertucci, Lucky Vujasin, Mark J Ratain
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 8 Issue 8 Pg. 2519-23 (Aug 2002) ISSN: 1078-0432 [Print] United States
PMID12171878 (Publication Type: Clinical Trial, Journal Article, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antineoplastic Agents
  • O(6)-benzylguanine
  • Guanine
  • O(6)-Methylguanine-DNA Methyltransferase
Topics
  • Aged
  • Aged, 80 and over
  • Animals
  • Antineoplastic Agents (pharmacology, therapeutic use)
  • CHO Cells
  • Cricetinae
  • DNA Methylation
  • DNA Repair
  • Dose-Response Relationship, Drug
  • Female
  • Guanine (analogs & derivatives, pharmacology, therapeutic use)
  • Humans
  • Male
  • Middle Aged
  • Neoplasms (drug therapy, surgery)
  • O(6)-Methylguanine-DNA Methyltransferase (antagonists & inhibitors, metabolism)
  • Tumor Cells, Cultured

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: